Novel process for the manufacturing of double-stranded RNA results in increased stability in biological fluids
Radebeul, Germany, July 17, 2013 / B3C newswire / – Riboxx Pharmaceuticals GmbH (Riboxx) today announced that the European Patent Office (EPO) has granted a patent on a novel process for the manufacturing of double-stranded RNA (dsRNA) bearing chemical modifications. This is the third patent granted by EPO for Riboxx’s technologies so far.
The chemical modification to the backbone of the dsRNA is designed to increase its resistance to enzymatic degradations by endonucleases and exonucleases that are present in biological fluids such as serum. The resulting in vivo stability of dsRNA manufactured under this process leads to significant increase in its potency compared to the intrinsically unstable dsRNA.
Dr. Jacques Rohayem, CEO of Riboxx said: “We are very proud to add another novel patent to the IP portfolio of Riboxx. One of the major drawbacks of RNA usage is in its instability in biological fluids. By using our new manufacturing process, both the stability of dsRNA be enhanced. A major field of application is immunomodulation by dsRNA molecules such as Toll-like Receptor 3 (TLR3) agonists. TLR3 agonists are important not just for use as vaccines adjuvants, but particularly in immunotherapy, where stability of TLR3 agonist in body fluids and tissues is crucial for its pharmacokinetics, with a direct impact on the efficacy of the treatment.”
About Riboxx Pharmaceuticals GmbH
Riboxx Pharmaceuticals GmbH is a DIN ISO 9001:2008 certified company focused on the development of molecules targeted to TLR3 with a direct application as vaccine adjuvants (Riboxxim®) and in immunotherapy (Riboxxon®). TLR3 agonists are key activators of dendritic cells and important players in innate immunity. The company engineers and manufactures TLR3 agonists, Riboxxim® and Riboxxon® to the highest possible quality standards. Today, Riboxx has on-going collaborations with both academic and industrial partners to advance the application of its TLR3 agonists in vaccination and immunotherapy. The company is headquartered in Radebeul, Germany.
About Riboxx´s manufacturing process of Toll-like Receptor 3 agonists
Riboxx has a proprietary process for manufacturing synthetic, highly pure and precisely defined nucleic acids molecules that are TLR3 agonists. The backbone structure, end modifications and lengths of the RNA strands can be easily adjusted and controlled by this biocatalytic process, thereby enabling the cost effective manufacturing of dsRNA that is fast, straight forward and easily scalable.
Dr. Jacques Rohayem